Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

GLP-1 receptor agonists may slightly reduce risk of fourteen obesity-related cancers for diabetics

Dr Lucas A Mavromatis - NYU Grossman School of Medicine, New York, USA
GLP-1 receptor agonists may slightly reduce risk of fourteen obesity-related cancers for diabetics ( Dr Lucas A Mavromatis - NYU Grossman School of Medicine, New York, USA )
2 Jun 2025

QoL improvements ID'd in phase 3 ARANOTE trial for mHSPC

Dr Alicia Morgans - Dana-Farber Cancer Institute, Boston, USA
QoL improvements ID'd in phase 3 ARANOTE trial for mHSPC ( Dr Alicia Morgans - Dana-Farber Cancer Institute, Boston, USA )
2 Jun 2025

Rusfertide shows promise for polycythemia vera treatment

Dr Andrew Kuykendall - Moffitt Cancer Center, Tampa, USA
Rusfertide shows promise for polycythemia vera treatment ( Dr Andrew Kuykendall - Moffitt Cancer Center, Tampa, USA )
1 Jun 2025

CtDNA monitoring of ER+/HER2- breast cancer during adjuvant endocrine therapy shows promise

Dr Lajos Pusztai - Yale School of Medicine, New Haven, USA
CtDNA monitoring of ER+/HER2- breast cancer during adjuvant endocrine therapy shows promise ( Dr Lajos Pusztai - Yale School of Medicine, New Haven, USA )
31 May 2025

Darolutamide plus ADT provides deep and durable PSA responses in metastatic hormone-sensitive prostate cancer

Prof Fred Saad - University of Montreal Hospital Center, Montreal, Canada
Darolutamide plus ADT provides deep and durable PSA responses in metastatic hormone-sensitive prostate cancer ( Prof Fred Saad - University of Montreal Hospital Center, Montreal, Canada )
27 Mar 2025

Enzalutamide with 5-ARI is safe for older patients with castration-sensitive systemic prostate cancer

Dr Sindhuja Kadambi - University of Rochester Medical Center, Rochester, USA
Enzalutamide with 5-ARI is safe for older patients with castration-sensitive systemic prostate cancer ( Dr Sindhuja Kadambi - University of Rochester Medical Center, Rochester, USA )
17 Mar 2025

Talazoparib and enzalutamide combination therapy shows significant benefit in treating mCRPC

Prof Neeraj Agarwal - University of Utah, Salt Lake City, USA
Talazoparib and enzalutamide combination therapy shows significant benefit in treating mCRPC ( Prof Neeraj Agarwal - University of Utah, Salt Lake City, USA )
5 Mar 2025

Everolimus plus lanreotide might be a new standard treatment in the first-line setting for grade 1/2 GEP-NETs

Dr Susumu Hijioka - National Cancer Center Hospital, Chuo City, Japan
Everolimus plus lanreotide might be a new standard treatment in the first-line setting for grade 1/2 GEP-NETs ( Dr Susumu Hijioka - National Cancer Center Hospital, Chuo City, Japan )
29 Jan 2025

Targeted therapies associated with increased risk for and incidence of thrombosis in the treatment of breast cancer

Dr James Martin - Cleveland Clinic, Cleveland, USA
Targeted therapies associated with increased risk for and incidence of thrombosis in the treatment of breast cancer ( Dr James Martin - Cleveland Clinic, Cleveland, USA )
20 Dec 2024

HER3-DXd demonstrates similar efficacy compared to multi-agent chemotherapy in high-risk HR-positive/HER2-negative eBC

Dr Mafalda Oliveira - Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
HER3-DXd demonstrates similar efficacy compared to multi-agent chemotherapy in high-risk HR-positive/HER2-negative eBC ( Dr Mafalda Oliveira - Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )
19 Dec 2024

Irradiation plus ADT with GnRH antagonist vs. GnRH agonist shows similar efficacy in high risk locally advanced PC

Dr Thomas Zilli - Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
Irradiation plus ADT with GnRH antagonist vs. GnRH agonist shows similar efficacy in high risk locally advanced PC ( Dr Thomas Zilli - Oncology Institute of Southern Switzerland, Bellinzona, Switzerland )
17 Dec 2024

EMUC 2024: Optimising strategies in mHSPC and mCRPC

Prof Gerhardt Attard, Prof Wolfgang Fendler, Dr Lynda Corrigan, Prof Jochen Walz
EMUC 2024: Optimising strategies in mHSPC and mCRPC ( Prof Gerhardt Attard, Prof Wolfgang Fendler, Dr Lynda Corrigan, Prof Jochen Walz )
13 Nov 2024